Clinical Research Organization
crobangladesh@gmail.com
+8801819251514
Clinical Trial of mRNA-based SARSCoV-2 vaccine in Rhesus macaque
GBPD060, BANGAVAX is the only SARSCoV-2 vaccine candidate that was developed by local scientists in Bangladesh. This is an mRNA based vaccine candidate and was included in the list of prospective COVID-19 vaccines by WHO.
A clinical trial to evaluate the immunogenicity and SARSCoV-2 neutralization in Rhesus macaque (Macaca mulatta) after immunization with GBPD060, BANGAVAX was conducted by CRO Ltd. successfully.
Sponsor of the clinical trial was Globe Biotech Ltd. Bangladesh. It was monitored by Directorate General of Drug Administration, Bangladesh, Bangabandhu Sheikh Mujib Medical University, Dhaka and Bangladesh Medical Research Council.
The clinical trial found GBPD060, BANGAVAX to safe and effective in Rhesus macaque and paved the way for a Phase I clinical trial of this COVID-19 vaccine candidate in humans.